Skip to main content
Clinical Trials/NCT01962259
NCT01962259CompletedNot Applicable

Active Commuting To Improve Well-being and Health in Everyday Life

University of Copenhagen1 site in 1 country188 target enrollmentStarted: November 1, 2013Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
188
Locations
1
Primary Endpoint
Peripheral insulin sensitivity (glucose clearance ml/min/kg fat-free mass/nM insulin)

Study Overview

Brief Summary

The aim of present randomized controlled trial is to evaluate the health effects of physical activity in transport and leisure time domains of everyday life and to develop durable physical activity regimens, i.e. to go from lifestyle intervention to daily lifestyle routine, in overweight individuals.

Subjects will be randomized to 1 of 4 groups. 1: Vigorous intensity leisure time physical activity, 2: Moderate intensity leisure time activity, 3: Active commuting by bicycle, or 4: a non-intervention control group

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
20 Years to 45 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •No engagement in habitual structured physical activity
  • •Body mass index 25-35 kg/m2
  • •Body fat percentage >32% for women and >25% for men
  • •Maximum oxygen uptake (VO2max) <40 ml O2/kg/min for women and <45 ml O2/kg/min for men
  • •Ethnicity: Caucasian

Exclusion Criteria

  • •Chronic use of medicine
  • •Fasting plasma glucose > 6,1 mmol/L
  • •Blood pressure > 140/90 mm Hg
  • •Abnormal resting and working ECG
  • •Parents or siblings with diagnosed type 2 diabetes
  • •For women: Follicle stimulating hormone (FSH) concentration > 35 milliunits/ml, pregnancy or planning of pregnancy within the coming year

Arms & Interventions

Control

No Intervention

Receives no intervention.

Vigorous intensity LTPA

Experimental

Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week

Intervention: Physical activity (Behavioral)

Moderate intensity LTPA

Experimental

Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week

Intervention: Physical activity (Behavioral)

Active commuting

Experimental

Bicycling to/from work/school/university. No requirements for exercise intensity; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week; Avg distance per day Females 9-15 km; Males 11-17 km

Intervention: Physical activity (Behavioral)

Outcomes

Primary Outcomes

Peripheral insulin sensitivity (glucose clearance ml/min/kg fat-free mass/nM insulin)

Time Frame: Change from baseline in peripheral insulin sensitivity at 6 months

Measured using the hyper-insulinemic euglycaemic clamp

Haemostatic balance

Time Frame: Change from baseline in endogenous thrombin potential at 6 months

Blood coagulation measured by fasting levels of endogenous thrombin potential (nM x min)

Peripheral insulin sensitivity (glucose clearance ml/min/kg fat-free mass/nM insulin)

Time Frame: Change from baseline in peripheral insulin sensitivity at 3 months

Measured using the hyper-insulinemic euglycaemic clamp

Haemostatic balance

Time Frame: Change from baseline in endogenous thrombin potential at 3 months

Blood coagulation measured by fasting levels of endogenous thrombin potential (nM x min)

Secondary Outcomes

  • Abdominal fat mass(Baseline, 3 and 6 months)
  • Health related quality of life and other psycho-social outcomes(Baseline, 3 and 6 months)
  • Anthropometry(Baseline, 3 and 6 months)
  • Sleep habits(Baseline, 3 and 6 months)
  • Subcutaneous adipose tissue biopsy(Baseline, 3 and 6 months)
  • Glycaemic control(Baseline, 3 and 6 months)
  • Haemostatic balance II(Baseline, 3 and 6 months)
  • Metabolic syndrome(Baseline, 3 and 6 months)
  • Central insulin sensitivity(Baseline, 3 and 6 months)
  • Maximal oxygen uptake (ml/O2/kg/min)(Baseline, 3 and 6 months)
  • Skeletal muscle biopsy(Baseline, 3 and 6 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Bente Merete Stallknecht

Professor

University of Copenhagen

Study Sites (1)

Loading locations...

Similar Trials